The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer.
CONCLUSION: There were no significant alterations in ECG in the acute period, indicated that ZA had no arrhythmia potential in the early period in patients with no underlying cardiac disease. However: patients receiving ZA should be monitored more closely because of the risk of arrhythmia which may ensue due to hypocalcemia, hypomagnesemia, or other chemotherapeutics.
PMID: 28740523 [PubMed]
Source: Clinical Cases in Mineral and Bone Metabolism - Category: Orthopaedics Tags: Clin Cases Miner Bone Metab Source Type: research
More News: Arrhythmia | Atrial Fibrillation | Cancer | Cancer & Oncology | Electrocardiogram | Reclast | Statistics | Study | Zometa